| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CV-6209 targets the platelet-activating factor (PAF) receptor. It acts as a potent antagonist. By blocking the PAF receptor, it inhibits PAF-induced platelet aggregation and other PAF-mediated effects. It is a selective PAF antagonist.
|
|---|---|
| ln Vitro |
CV-6209 reduces PAF (30 nM)-stimulated [3H]serotonin release from rabbit platelets [1]. CV-6209 has no effect on platelet aggregation caused by arachidonic acid, ADP, or collagen [1]. CV-6209 (0.2-2 μM; 30 min pretreatment) suppresses PAF-induced MC degranulation in LAD2 and hLMC [1].
CV-6209 inhibits PAF-induced rabbit and human platelet aggregation with IC50 values of 75 nM and 170 nM, respectively. It has antiproliferative effects. It partially inhibits acetylcholine-induced hypotension. It inhibits PAF-induced PMN or platelet aggregation. |
| ln Vivo |
CV-6209 (iv) shows a favorable reaction to arachidonic acid, histamine, bradykinin, and isoproterenol-induced hypotension in rats (ED50=0.009 mg/kg) and reduces PAF (0.3 μg/kg; iv)-induced hypotension. Hypotension doesn't matter [1]. Asparaginase-induced hypersensitivity was lessened by CV-6209 (66 μg; i.v.) when compared to sensitized mice that were not pretreated [3].
CV-6209 has anti-Helicobacter pylori effects. It inhibits PAF-induced hypotension in rats. It is used as a pharmacological tool to dissect PAF-mediated pathways in inflammation, thrombosis, and cardiovascular research. |
| Enzyme Assay |
CV-6209 is evaluated in cell-free receptor binding assays to determine its affinity for the PAF receptor. Radioligand binding displacement assays are performed using membrane preparations expressing PAF receptors. Competition binding experiments are conducted with increasing concentrations of CV-6209 and a fixed concentration of a labeled reference ligand.
|
| Cell Assay |
CV-6209 is assessed in cell-based assays using platelets and other cell types. Platelets are treated with CV-6209, and PAF-induced aggregation is measured using aggregometry. The compound's effects on cell proliferation and signaling are evaluated.
|
| Animal Protocol |
CV-6209 is administered in animal models to evaluate its effects on PAF-mediated inflammation and thrombosis. It inhibits PAF-induced hypotension in rats. Efficacy is assessed by measuring platelet aggregation, blood pressure, and inflammatory markers.
|
| ADME/Pharmacokinetics |
CV-6209 has a molecular weight of 642.31 and a molecular formula of C34H56N2O6. It has a CAS number of 100488-87-7. The compound is soluble in DMSO. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for CV-6209. The compound is for research use only and is not intended for human therapeutic use. It is a potent PAF receptor antagonist.
|
| References |
|
| Additional Infomation |
CV-6209 is a potent PAF receptor antagonist. It is a synthetic, cationic, ether-linked phospholipid analog. It is used in research on inflammation, thrombosis, and cardiovascular disease. It is not approved for clinical use.
|
| Molecular Formula |
C34H60N3O6+
|
|---|---|
| Molecular Weight |
606.87
|
| Exact Mass |
641.417
|
| CAS # |
100488-87-7
|
| PubChem CID |
107756
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
8.674
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
27
|
| Heavy Atom Count |
44
|
| Complexity |
722
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
APUCCVGQZPNXIO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C34H59N3O6.ClH/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-25-35-33(39)42-28-32(41-4)29-43-34(40)37(30(3)38)27-31-24-21-23-26-36(31)6-2;/h21,23-24,26,32H,5-20,22,25,27-29H2,1-4H3;1H
|
| Chemical Name |
[2-methoxy-3-(octadecylcarbamoyloxy)propyl] N-acetyl-N-[(1-ethylpyridin-1-ium-2-yl)methyl]carbamate;chloride
|
| Synonyms |
CV6209; CV 6209; CV-6209
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~155.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6478 mL | 8.2390 mL | 16.4780 mL | |
| 5 mM | 0.3296 mL | 1.6478 mL | 3.2956 mL | |
| 10 mM | 0.1648 mL | 0.8239 mL | 1.6478 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
